Johnson & Johnson [JNJ] stock is trading at $164.14, up 2.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JNJ shares have gain 2.18% over the last week, with a monthly amount glided 12.66%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Johnson & Johnson [NYSE: JNJ] stock has seen the most recent analyst activity on July 23, 2024, when Daiwa Securities downgraded its rating to a Neutral and also revised its price target to $150 from $160. On April 18, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $170 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $163 on December 13, 2023. UBS upgraded its rating to a Buy and raised its price target to $180 on December 01, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on October 05, 2023, and assigned it a price target of $178. In a note dated September 06, 2023, HSBC Securities initiated an Hold rating and provided a target price of $175 on this stock.
Johnson & Johnson [JNJ] stock has fluctuated between $143.13 and $175.97 over the past year. Currently, Wall Street analysts expect the stock to reach $176.29 within the next 12 months. Johnson & Johnson [NYSE: JNJ] shares were valued at $164.14 at the most recent close of the market. An investor can expect a potential return of 7.4% based on the average JNJ price forecast.
Analyzing the JNJ fundamentals
Johnson & Johnson [NYSE:JNJ] reported sales of 86.57B for the trailing twelve months, which represents a drop of -12.12%. Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.44%. To continue investigating profitability, this company’s Return on Assets is posted at 0.21, Equity is 0.54 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 161.81 points at the first support level, and at 159.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 165.66, and for the 2nd resistance point, it is at 167.18.
Ratios To Look Out For
For context, Johnson & Johnson’s Current Ratio is 1.07. As well, the Quick Ratio is 0.85, while the Cash Ratio is 0.46. Considering the valuation of this stock, the price to sales ratio is 4.56, the price to book ratio is 5.52 and price to earnings (TTM) ratio is 23.73.
Transactions by insiders
Recent insider trading involved Broadhurst Vanessa, EVP, Global Corp Affairs, that happened on Mar 13 ’24 when 8891.0 shares were sold. 10% Owner, JOHNSON & JOHNSON completed a deal on Feb 16 ’24 to sell 3725.0 shares. Meanwhile, EVP, WW Chair, Pharmaceuticals Taubert Jennifer L sold 59397.0 shares on Feb 09 ’24.
